Trichoderma: A Comprehensive Reference
1. Identity: Taxonomy, Natural Sources, and Common Forms
1.1 Taxonomic Classification
Trichoderma is a fungal genus that was described in 1794, including anamorphic fungi isolated primarily from soil and decomposing organic matter. As per Kirk's classification, taxonomy based on molecular phylogeny in the Ainsworth and Bisby's Dictionary of Fungi (10th edition), the teleomorphic stage of the genus Trichoderma belongs to the domain Eukarya, kingdom Fungi, phylum Ascomycota, class Sordariomycetes, subclass Hypocreomycetidae, order Hypocreales, family Hypocreaceae. The genera Hypocrea, Podostroma, and Sarawakus, belonging to the family Hypocreaceae (Ascomycetes), have also been described as teleomorphs of Trichoderma.
The genus was described by Christiaan Hendrik Persoon in 1794, but the taxonomy has remained difficult to resolve. For a long time, it was considered to consist of only one species, Trichoderma viride, named for producing green mold. Most of the Trichoderma species are morphologically very similar and were considered for many years as a single species, T. viride. A consolidated taxonomical scheme was needed. Rifai (1969) proposed and defined nine morphological species aggregates. The genus was originally established by Persoon, who described four species, including T. aureum, T. nigrescens, T. roseum, and T. viride, based on morphological characterisations. However, subsequent research has shown that these species are unrelated to each other, and only T. viride remains classified within Trichoderma.
A total of 75 Trichoderma species have been identified; the majority of which are considered as important microbial biological control agents. These include T. harzianum, T. hamatum, T. koningii, T. polysporum, and T. virens. Medically and industrially significant species further include Trichoderma reesei, Trichoderma longibrachiatum, Trichoderma asperellum, Trichoderma atroviride, and Trichoderma viride.
1.2 Natural Sources and Habitats
Trichoderma is a genus of fungi in the family Hypocreaceae that is present in all soils, where they are the most prevalent culturable fungi. Many species in this genus can be characterized as opportunistic avirulent plant symbionts, referring to the ability of several Trichoderma species to form mutualistic endophytic relationships with several plant species. Trichoderma species are common fungi usually found in humid soil, decaying wood, and water-related sites. These species are often isolated from soils across diverse ecosystems, including agricultural fields, forests, deserts, and aquatic environments such as freshwater and marine systems.
Trichoderma spp. are highly available in all types of soils, and most of these species are avirulent and opportunistic fungi. Trichoderma species of the order Hypocreales (Ascomycota) comprise a large number of saprobic species with a worldwide distribution. They are commonly found in soil and play an important role as decomposers of decaying plant material and insect pathogens.
1.3 Common Forms, Preparations, and Supplement Uses
In the context of dietary supplementation and food processing, Trichoderma β particularly T. reesei and T. longibrachiatum β is primarily encountered not as a whole organism but as a source of derived enzyme preparations, most notably cellulase. Cellulase is an enzyme derived from the fungi Aspergillus niger and Trichoderma longibrachiatum or other sources. Cellulose is an indigestible plant polysaccharide and the principal constituent of the cell wall of plants. Cellulase has cellulolytic activity, meaning that it hydrolyzes cellulose.
Cellulase derived from Trichoderma longibrachiatum is comprised of an enzyme complex consisting of cellulase, a glucosidase, cellobiohydrolase, and a glucanase. This complex converts cellulose to beta-dextrins and ultimately to D-glucose.
Sources of cellulase for enzyme supplements may be Aspergillus niger, Trichoderma longibrachiatum, and Trichoderma reesei; preferably the enzyme is from Trichoderma longibrachiatum. It is used as a digestive enzyme, and dosage should not exceed 110,000 CU (cellulose units) per day, and should be taken with food/meal.
In animal nutrition research, Trichoderma reesei-derived enzymes in powder and liquid forms have been studied on diet supplementation; the diets composed of corn and soybean meal were evaluated for their effects on performance, digestibility, blood parameters, and the biometry of the digestive system, with cellulases affecting feed intake and digestibility.
Beyond enzymes, Trichoderma itself appears in agriculture as living formulations β biofertilizers and biocontrol spore preparations β applied to soils and plant roots. These are not the same as human dietary supplements; direct human oral supplementation with live Trichoderma organisms is not an established practice documented in the peer-reviewed literature.
2. Traditional and Historical Use
Trichoderma does not carry a documented history in traditional human medicine in the same way that macrofungi such as Ganoderma or Inonotus obliquus (Chaga) do. There are no recorded entries in major ethnobotanical traditions β including Ayurveda, Traditional Chinese Medicine, or European folk medicine β that specifically document the intentional use of Trichoderma species as a medicinal agent for human consumption.
The historical significance of Trichoderma lies primarily in agriculture. Trichoderma fungi have for long been reported as decomposers; many authors have reported them as saprobic organisms, while many reports are emerging on many species of Trichoderma as mycoparasitic and endophytic organisms. Scientific interest in the genus accelerated from the mid-20th century onwards with the discovery of antibiotic metabolites produced by T. viride and the development of the first agricultural biocontrol products.
The first formal taxonomic description of the genus dates to 1794 (Persoon), but systematic scientific study of its secondary metabolites and biotechnological applications did not advance in earnest until the latter half of the 20th century. The production of secondary metabolites by Trichoderma strains shows great variety and application potential in the medicinal field. Trichoderma viride is a source of antibiotics through transformation of acetaldehydes, gliotoxin, and viridin to alpha-pyrones.
The use of Trichoderma reesei-derived cellulase enzymes in food processing and animal nutrition is a 20th-century industrial development, not a continuation of traditional medicine practice.
3. Key Constituents and Active Compounds
To date, nearly 200 Trichoderma sp. compounds have been identified as terpenoids, polyketides, peptides, alkaloids, and lactones. Filamentous fungi from soil ecosystems have gained attention as reservoirs of such metabolites, including those with antimicrobial, antioxidant, and cytotoxic activities. These fungi produce a wide range of secondary metabolites, such as alkaloids, flavonoids, phenols, steroids, and terpenoids, that play key roles in ecological interactions and show potential for pharmaceutical development.
3.1 Peptaibols
Peptaibols are linear peptides consisting of Ξ±,Ξ±-dialkylated amino acids, isovaline, Ξ±-amino isobutyric acid (Aib), an acetylated N-terminus, and a C-terminal amino alcohol. They are ecologically and commercially important for their antimicrobial and anti-cancer properties, as well as their ability to induce systemic resistance in plants against microbial invasion. The peptaibols are amphipathic in nature and self-assemble to form voltage-dependent ion channels in membranes. This ability is largely responsible for the antibiotic properties of these compounds. Peptaibols are produced largely by members of the genus Trichoderma, and the first discovered peptaibol, alamethicin F30, was reported from T. viride.
Trichoderma species, including Trichoderma reesei, are capable of producing metabolites called peptaibols. Some Trichoderma reesei strains can produce the peptaibol paracelsin as well as other peptaibols. Paracelsin is reported to be harmful to aquatic invertebrates, to mammalian cells, and to mice in experimental conditions where natural barriers were bypassed.
3.2 Gliotoxin and Viridin
A wide variety of compounds have been identified during the interaction between T. harzianum and Rhizoctonia solani, such as heptelidic acid, trichoviridine, harzianic acid, gliotoxin, glioviridin, viridin, and viridiol.
Some strains of Trichoderma virens produce gliotoxin, a fungal epidithiodioxopiperazine (ETP)-type secondary metabolite that is toxic to animal cells. It induces apoptosis, prevents NF-ΞΊB activation via the inhibition of the proteasome, and has immunosuppressive properties. Gliotoxin is known to be involved in the antagonism of rhizosphere microorganisms. In animal models, damage to cells is well-documented, as are the induction of apoptosis and interferences with NF-ΞΊB signaling and proteasome function. The mechanism is, at least in part, oxidative stress catalyzed by gliotoxin, which is a redox-active molecule. Immunosuppression is apparently the result of this multiple damage, which interferes with neutrophil activity.
Gliotoxin (GT) is a dual fungal secondary metabolite. It displays pleiotropic activities and possesses medicinal properties and biocontrol abilities but, unfortunately, has toxic properties in humans.
3.3 Harzianic Acid and Related Polyketides
Harzianic acid, a tetramic acid produced by the T. harzianum M10 strain, demonstrated remarkable biological properties, including plant growth promotion and antimicrobial activity against different plant pathogenic fungi, such as Pythium irregulare, Sclerotinia sclerotiorum, and R. solani.
3.4 Terpenoids and Steroids
The biocontrol fungus Trichoderma harzianum, from both marine and terrestrial environments, has attracted considerable attention. T. harzianum has a tremendous potential to produce a variety of bioactive secondary metabolites (SMs), which are an important source of new herbicides and antibiotics. Marine-derived SMs, especially terpenoids, polyketides, and macrolide compounds, occupy a significant proportion of natural products from T. harzianum.
Stigmasterol was obtained from T. harzianum and T. koningii, showing antifungal activities against R. solani, S. rolfsii, M. phaseolina, and F. oxysporum. Sesquiterpenes from Trichoderma have demonstrated antibacterial, antifungal, and neuroleptic activities. One particular group of sesquiterpenes includes fungal toxins known as trichothecenes. There are different species of Trichoderma producing bioactive compounds that act as a mycotoxin such as Trichothecene. It is a sesquiterpenoid-derived secondary metabolite synthesized mainly by Fusarium and other fungal genera such as Trichoderma, Trichothecium, and Stachybotrys.
3.5 Cellulases and Industrial Enzymes
Trichoderma reesei-derived cellulase (systematic name: 4-(1,3;1,4)-Ξ²-D-glucan 4-glucanohydrolase; EC 3.2.1.4) catalyses the hydrolysis of 1,4-Ξ²-D-glucosidic linkages in cellulose, lichenin, and cereal Ξ²-D-glucans, resulting in the generation of mono, di-, tri-, tetra-, and oligosaccharides composed of glucose residues. Trichoderma reesei is efficient in the production of cellulase, which is produced via submerged fermentation followed by purification, formulation, and drying.
3.6 Anthraquinones and Other Phenolic Compounds
Three anthraquinones β 1,8-dihydroxy-3-methylanthraquinone, 1-hydroxy-3-methylanthraquinone, and 6-methyl-1,3,8-trihydroxyanthraquinone β were isolated from T. harzianum strains that were active against R. solani, S. rolfsii, M. phaseolina, and F. oxysporum. Polyphenolic compounds have been recognized to possess pharmacological properties such as antioxidative, hepatoprotective, antibacterial, anti-inflammatory, anticancer, and potential antiviral properties.
Genome analysis of T. afroharzianum reveals biosynthetic gene clusters for the biosynthesis of polyketides, non-ribosomal peptides, and terpenes, underscoring the genus's potential for producing bioactive compounds.
4. Scientific Evidence by Area of Use
4.1 Antimicrobial Activity (In Vitro and Preclinical)
Organic extracts from T. afroharzianum strains demonstrated broad-spectrum antimicrobial activity, inhibiting Gram-positive and Gram-negative bacteria, as well as various Candida species, with notable efficacy against Staphylococcus aureus (MICs: 15.6β31.25 Β΅g/mL). The extracts also showed antibiofilm activity, with the UEPA AR12 strain exhibiting the highest inhibition against Escherichia coli (81.8%), Enterococcus faecalis (92.8%), Candida albicans (87.9%), and Candida parapsilosis (89.3%).
The two Trichoderma strains tested in one study β T. asperellum IMI 393899 and T. atroviride TS β inhibited the growth of tested pathogens when they came in contact with them. The extract of T. asperellum showed the highest inhibition activity and was active even at a low concentration. Both Trichoderma strains produced compounds with antifungal activity against the pathogenic fungi and oomycetes tested.
Evidence strength: All antimicrobial findings in the context of human health are currently limited to in vitro laboratory studies. No clinical trials in humans evaluating Trichoderma-derived extracts as antimicrobial agents have been identified in the peer-reviewed literature.
4.2 Antioxidant Activity (In Vitro)
Strong antifungal activity of T. harzianum extracts was identified, and the IC50 of antioxidant activity was estimated for ethyl acetate extract at 71.47% and n-butanol extract at 56.01%, using the DPPH test. Trichoderma harzianum VOCs play a significant role as antifungal and antioxidant agents given the advantageous bioactive chemicals noted in the extracts.
T. hamatum also possesses several beneficial activities, such as antimicrobial activity and antioxidant activity.
Evidence strength: Antioxidant activity has been demonstrated exclusively in in vitro assays (DPPH and similar radical-scavenging tests). No human clinical evidence for antioxidant effects in vivo exists.
4.3 Cytotoxic and Anticancer Properties (In Vitro and Computational)
Several recent studies have investigated the cytotoxicity of natural extracts against human cancer cell lines, where proliferation and viability of cancer cells were decreased after treatment with natural extracts. Cytotoxic activities of Trichoderma spp. against liver cancer cell lines have not been studied enough, and one research group reported the first study using metabolites of the whole culture filtrate of Trichoderma viride as anticancer agents.
Computational studies have explored anticancer potential. Secondary metabolites of Trichoderma spp. have been evaluated as EGFR tyrosine kinase inhibitors through a computational approach assessing anticancer efficacy.
Peptaibols are ecologically and commercially important for their antimicrobial and anti-cancer properties.
Evidence strength: Anticancer investigation is exclusively preclinical β limited to in vitro cell line studies and in silico (computational) analyses. No clinical trials in human cancer patients have been conducted with Trichoderma-derived metabolites as therapeutic agents.
4.4 Digestive Enzyme Supplementation (Limited Human Data)
Cellulase has been used to address phytobezoars, a form of cellulose bezoar found in the human stomach. Cellulase is used as a digestive aid, particularly in animals, and for the management of flatulence.
One study of nursing home patients taking a multi-enzyme formula containing cellulase found that they favorably increased markers of protein absorption, indicating an improvement in digestion of a nutritional formula also given to the study participants, which would lead to an overall better nutritional status. Other tests also indicated an improvement in immune function for the patients. When the enzyme supplement was withdrawn, the positive benefits ended. This study involved a multi-enzyme formula β not a Trichoderma-specific product β and thus cannot be attributed solely to T. longibrachiatum-derived cellulase.
The cellulase from T. reesei catalyses the hydrolysis of 1,4-Ξ²-D-glucosidic linkages in cellulose, lichenin, and cereal Ξ²-D-glucans. It is intended to be used in brewing processes, distilled alcohol production, and starch processing for the production of glucose syrups.
Evidence strength: The use of Trichoderma-derived cellulase as a food enzyme is regulated and safety-assessed (see European Food Safety Authority review below). However, controlled human clinical trials specifically evaluating its digestive efficacy in humans are sparse, and where multi-enzyme formulations have been studied, the independent contribution of cellulase cannot be isolated.
4.5 Agricultural Enhancement of Food Nutrient Content (Preclinical Indirect Evidence)
One line of research investigates whether Trichoderma inoculation of food crops increases the nutritional value of the resulting food. In order to increase the productivity of Brassica crops and improve their glucosinolate content and antioxidant capacity, different strategies can be considered, including symbiosis with endophytic fungi. This is relevant only insofar as the secondary compounds in Trichoderma-treated plants may be more nutritious; the fungus itself is not consumed by humans in this context.
5. Body Systems and Health Areas Associated with Trichoderma
- Digestive System: Trichoderma-derived cellulase is used as a food enzyme and digestive supplement to hydrolyze cellulose; industrial preparations are approved for use in food processing by regulatory bodies including the European Food Safety Authority (EFSA).
- Immune System (in vitro / preclinical): Gliotoxin, produced by some Trichoderma strains, is a potent immunosuppressive compound shown to interfere with NF-ΞΊB signaling, inhibit the proteasome, induce apoptosis, and suppress neutrophil function in laboratory settings. These properties are relevant to safety rather than therapeutic benefit.
- Oncology (in vitro / computational only): Several secondary metabolites β peptaibols, terpenoids, anthraquinones β have demonstrated in vitro cytotoxicity against human cancer cell lines. No human clinical evidence exists.
- Antimicrobial (in vitro only): Extracts show activity against both bacterial and fungal pathogens in laboratory settings.
- Infectious Disease (clinical safety concern): Several species are recognized as opportunistic human pathogens. See Section 7 (Safety).
6. Dosage Forms and Reported Dosages
In the context of cellulase supplementation sourced from Trichoderma longibrachiatum, dosage should not exceed 110,000 CU (cellulose units) per day, and should be taken with food/meal.
For the T. reesei-derived food enzyme cellulase (strain DP-Nzc36), the European Food Safety Authority (EFSA) Panel identified a no-observed adverse effect level of at least 97.6 mg TOS (total organic solids)/kg body weight per day, which, compared to the estimated dietary exposure, results in a margin of exposure of at least 745.
In the agricultural and animal nutrition literature, Trichoderma reesei-derived enzymes in powder and liquid forms were studied on the feeding of broiler chickens from 1 to 21 days of age in diets composed of corn and soybean meal, with effects evaluated on performance, digestibility, blood parameters, and biometry of the digestive system. Specific dosages for human supplementation with whole Trichoderma organisms are not documented in peer-reviewed clinical literature, as such use is not an established practice.
7. Safety Considerations and Notable Interactions
7.1 Opportunistic Pathogenicity (Trichodermosis)
The spectrum of filamentous fungi emerging as opportunistic human pathogens is widening constantly. Various types of mycoses with often severe, occasionally even fatal outcome have been attributed to different species of the genus Trichoderma, usually in patients with an impaired immune system. However, cases involving non-immunocompromised hosts are also known. For these infections, the name "trichodermosis" has been proposed. Trichoderma may cause (rhino)sinusitis; otitis externa; lung, central nervous system (CNS), liver, and skin infections; stomatitis; peritonitis; endocarditis; onychomycosis; keratitis; and disseminated infections.
Predisposing conditions include organ transplantation, peritoneal dialysis, hematological malignancies, and HIV infection.
Currently, nine species of pathogens are believed to cause diseases in humans: Trichoderma citrinoviride, Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma orientale, Trichoderma pseudokoningii, Trichoderma reesei, and Trichoderma viride.
Trichoderma species are filamentous fungi responsible for localized and threatening invasive infections causing up to 53% mortality in immunocompromised patients. Nine species have been reported as potential human pathogens.
After 50 years of case reporting (first case in 1970 to 2019), 42 cases or episodes of Trichoderma infection in humans were recorded. In the maximum number of cases, T. longibrachiatum was involved.
A review of 40 cases of infection associated with Trichoderma spp., mostly T. longibrachiatum, has been published. The number of reported cases has grown from year to year, possibly because of the expanding population of immunocompromised hosts.
A case report presents a noteworthy instance of Trichoderma harzianum causing fungaemia in an immunocompetent individual, illustrating the potential for severe infections even in individuals who do not fall into traditional risk groups.
7.2 Antifungal Drug Resistance
Data concerning the antifungal susceptibilities of clinical Trichoderma isolates indicate high levels of resistance to the antifungal drugs used routinely, which may cause difficulties in the treatment of infected patients. Antifungal susceptibility data often correlate with the taxonomic position of isolates; therefore, accurate identification of opportunistic fungi is crucial for adequate therapeutic interventions.
Trichoderma infections in humans have been related with several risk factors, being associated mostly with peritoneal dialysis, organ transplantation, and hematologic disorders. They cause severe and persistent disseminated infections that usually fail to respond to treatment with amphotericin B or voriconazole.
7.3 Gliotoxin Toxicity
The discovery of gliotoxin in an opportunistic human pathogen and the establishment of its role in virulence led to this strong antimicrobial metabolite being designated as a mycotoxin. Gliotoxin displays pleiotropic activities and possesses medicinal properties and biocontrol abilities but has toxic properties in humans.
7.4 Trichothecene and Sesquiterpene Toxins
Trichothecene is a sesquiterpenoid-derived secondary metabolite synthesized by Trichoderma and other fungal genera. These sesquiterpenoid compounds are harmful to plants and animals that feed on infected fodder.
7.5 Peptaibol Toxicity
Paracelsin, a peptaibol produced by some Trichoderma reesei strains, is reported to be harmful to aquatic invertebrates, to mammalian cells, and to mice in experimental conditions where natural barriers were bypassed.
7.6 EFSA Safety Assessment of Cellulase from T. reesei
Similarity of the amino acid sequence of T. reesei-derived cellulase to known allergens was searched, and no match was found. The EFSA Panel considered that, under the intended conditions of use, the risk of allergic sensitisation and elicitation reactions by dietary exposure can be excluded in distilled alcohol production and is considered to be low when the enzyme is used in starch processing and brewing processes. Based on the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns under the intended conditions of use.
7.7 Occupational Exposure
Although the vast majority of biological control agents are generally regarded as safe for humans and the environment, some studies have demonstrated that increased exposure to fungal substances among agricultural workers may affect the immune system.
7.8 General Pathogenicity Assessment
There is a reasonable certainty of no harm to human adults, infants, and children exposed to Trichoderma harzianum strain T-39. This includes all anticipated dietary exposures and all other exposures evaluated with the current database.
There is no evidence in the scientific literature indicating that Trichoderma reesei strain ATCC 74252 is likely to have adverse effects on human health. Trichoderma reesei is unlikely to cause infection in humans. In the unlikely event of infection, Trichoderma reesei strain ATCC 74252 is susceptible to major clinical antifungal drugs.
Summary of Evidence Limitations
The overwhelming majority of data on Trichoderma's potential bioactive properties β antimicrobial, antioxidant, cytotoxic β derives from in vitro laboratory experiments and, to a lesser extent, animal studies. No robust, peer-reviewed randomized controlled trials in human populations have evaluated any whole Trichoderma preparation or isolated metabolite (other than purified cellulase enzyme in food processing contexts) for therapeutic benefit. The use of Trichoderma-derived cellulase as a human dietary supplement ingredient has regulatory safety support (EFSA, EPA), but clinical efficacy evidence in human digestion remains limited and indirect. Furthermore, several species carry meaningful safety concerns as emerging opportunistic pathogens, particularly for immunocompromised individuals. Characterizing Trichoderma broadly as a safe human health supplement therefore lacks sufficient scientific grounding; its recognized legitimate roles are in agriculture, industrial enzyme production, and food processing.
References
Go back